HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of the SEQuoia RiboDepletion Kit, which improves assay efficiency by eliminating irrelevant ribosomal RNA (rRNA) fragments from an RNA-Seq library.

The SEQuoia RiboDepletion Kit is designed for genomics researchers targeting rare transcripts or working with a limited or degraded sample. The kit can retain RNA transcripts that could be lost when using other methods. In addition, the efficient elimination of irrelevant rRNA fragments helps reduce the costs of sequencing RNA samples.

“Using the SEQuoia RiboDepletion Kit, genomics researchers can obtain the highest quality sequencing data while improving efficiencies and saving costs,” said Steven Blakely, Bio-Rad Global Director of Marketing, Life Science Group, Gene Expression. “We are excited to expand our SEQuoia product line, which complements our portfolio of genomic research products that enable easy integration into NGS workflows,” he said.

Key Benefits of the SEQuoia RiboDepletion Kit

• Improves assay sensitivity by eliminating irrelevant rRNA fragments from an RNA-Seq library
• Retains rare transcripts commonly lost from a pre-library RNA depletion strategy
• Enables the pooling of multiple libraries into one depletion reaction to save time and reduce costs
• Streamlines workflow to less than two hours
• Works with a broad input range and is compatible with most available library prep kits

The SEQuoia RiboDepletion Kit is the latest offering in Bio-Rad’s SEQuoia portfolio, an RNA-Seq sample preparation product family.

Please visit bio-rad.com/SEQuoiaRiboDepletion to learn more.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 7,800 employees worldwide. Bio-Rad had revenues exceeding $2.5 billion in 2020. For more information, please visit bio-rad.com.

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.